HR23B is a biomarker for tumor sensitivity to HDAC inhibitor-based therapy
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
Histone deacetylase (HDAC) inhibitors are emergent cancer drugs. HR23B is a candidate cancer biomarker identified in a genome-wide loss-of-function screen which influences sensitivity to HDAC inhibitors. Because HDAC inhibitors have found clinical utility in cutaneous T-cell lymphoma (CTCL), we evaluated the role of HR23B in CTCL cells. Our results show that HR23B governs the sensitivity of CTCL cells to HDAC inhibitors. Furthermore, proteasome activity is deregulated in HDAC inhibitor-treated CTCL cells through a mechanism dependent upon HR23B, and HDAC inhibitors sensitize CTCL cells to the effects of proteasome inhibitors. The predictive power of HR23B for clinical response to HDAC inhibitors was investigated through an analysis of a unique collection of CTCL biopsies taken from a phase II clinical trial, where there was a frequent coincidence between HR23B expression and clinical response to HDAC inhibitor. Our study supports the personalized medicine approach for treating cancer and the increasing drive to translate laboratory-based findings into clinical utility.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Histone deacetylases and cancer: causes and therapies
Marks, P. A., Rifkind, R. A., Richon, V. M., Breslow, R., Miller, T., & Kelly, W. K. (2001) · Nature reviews. Cancer · doi:10.1038/35106079 · Cited by 1,866 · cited 1×
“HDAC is a family of enzymes that regulate the acetylation level of chromatin, together with a variety of nonhistone proteins (3).”
BackgroundDuvic, M., Talpur, R., Ni, X., Zhang, C., Hazarika, P., Kelly, C., Chiao, J. H., Reilly, J. F., Ricker, J. L., Richon, V. M., et al. (2007) · Blood · doi:10.1182/blood-2006-06-025999 · Cited by 1,141 · cited 4×
“HDAC inhibitor treatment is significantly better than the existing frequency of response in unselected patients (9, 11).”
BackgroundMethodInfluentialSelf-citationHDAC6 controls autophagosome maturation essential for ubiquitin‐selective quality‐control autophagy
Lee, J., Koga, H., Kawaguchi, Y., Tang, W., Wong, E., Gao, Y., Pandey, U. B., Kaushik, S., Tresse, E., Lu, J., et al. (2010) · The EMBO Journal · doi:10.1038/emboj.2009.405 · Cited by 756 · cited 1×
“Indeed, under some circumstances, this outcome could influence autophagy (22).”
BackgroundHistone deacetylase inhibitors as new cancer drugs
Marks, P. A., Richon, V. M., Breslow, R., & Rifkind, R. A. (2001) · Current Opinion in Oncology · doi:10.1097/00001622-200111000-00010 · Cited by 531
Fotheringham, S., Epping, M. T., Stimson, L., Khan, O., Wood, V., Pezzella, F., Bernards, R., & La Thangue, N. B. (2009) · Cancer Cell · doi:10.1016/j.ccr.2008.12.001 · Cited by 138
Self-citation
Cited by
Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders
Falkenberg, K. J., & Johnstone, R. W. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4360 · Cited by 1,564
New and emerging HDAC inhibitors for cancer treatment
West, A. C., & Johnstone, R. W. (2014) · Journal of Clinical Investigation · doi:10.1172/jci69738 · Cited by 1,404
“Subsequent studies showed a correlation between HR23B expression and clinical response to vorinostat (48), and the interaction between Hsp90 and HDAC6 was identified as being the crucial functional effector mechanism delineating relative sensitivity”
Advances in targeted therapies for hepatocellular carcinoma in the genomic era
Llovet, J. M., Villanueva, A., Lachenmayer, A., & Finn, R. S. (2015) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2015.103 · Cited by 621
HDAC inhibitors in cancer biology: emerging mechanisms and clinical applications
Khan, O., & La Thangue, N. B. (2012) · Immunology & Cell Biology · doi:10.1038/icb.2011.100 · Cited by 450
Self-citationHistone deacetylase (HDAC) inhibitors in recent clinical trials for cancer therapy
Wagner, J. M., Hackanson, B., Lübbert, M., & Jung, M. (2010) · Clinical Epigenetics · doi:10.1007/s13148-010-0012-4 · Cited by 338
Metadata
- Authors
- Khan, O., Fotheringham, S., Wood, V., Stimson, L., Zhang, C., Pezzella, F., Duvic, M., Kerr, D. J., & La Thangue, N. B.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 2010-03-22
- Volume
- 107
- Issue
- 14
- Pages
- 6532-6537
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2057358066
- Cited by
- 152
- References
- 5
- FWCI
- 6.73
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: HR23B is a biomarker for tumor sensitivity to HDAC inhibitor-based therapy. https://app.cochat.ai/papers/10.1073/pnas.0913912107
- The paper
- Khan, O., Fotheringham, S., Wood, V., Stimson, L., Zhang, C., Pezzella, F., Duvic, M., Kerr, D. J., & La Thangue, N. B. (2010). HR23B is a biomarker for tumor sensitivity to HDAC inhibitor-based therapy. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.0913912107
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.